Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart surgery blood filter shows kidney protection promise in new analysis

NCT ID NCT06781294

Knowledge-focused Sponsor: Hospital Universitari de Bellvitge Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 01, 2026 · Updated 3 times

Summary

This study re-analyzes data from a previous trial of 343 heart surgery patients who received a blood purification device (oXiris) connected to the heart-lung machine. The original trial found a 12% reduction in acute kidney injury within 7 days. Now researchers will examine how the filter affects antibiotics, heparin, and other drugs, and whether certain patient groups benefit more. The goal is to better understand the device's safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Extracorporeal cytokine hemadsorption device (oXiris)
What this could lead to
If successful, this analysis could clarify how best to use blood purification during heart surgery to protect kidneys and guide safe antibiotic dosing.
What could go wrong
This is a post-hoc analysis of an already completed trial, not a new experiment. Findings may be less reliable and need confirmation in future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

343 people

The number who actually took part.

Started

Oct 2024

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Non emergent cardiac surgery requiring cardiopulmonary bypass with expected CPB time over 90 minutes (double valve replacement or valve replacement plus CABG). * Written informed consent from patient or legal surrogates. Exclusion Criteria: * Transplant receptor. * Advanced Chronic Kidney Disease (CKD 4 or 5). * Renal replacement therapy in the last 90 days. * Documented intolerance to study device. * Inclusion in other ongoing study within the last 30 days. * Pregnancy. * Immunosuppressive treatment or steroids (prednisone \> 0.5 mg/kg/day or equivalent). * Autoimmune disorder. * Coexisting illness with a high probability of death (inferior to 6 months).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury chronic kidney disease chronic renal failure syndrome Insulin Resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Cardiac surgery requiring cardiopulmonary bypass Chronic kidney disease (CKD) Kidney failure, acute

Contacts and locations

Locations

  • Universitat de Barcelona

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.